Zhejiang Renzhi (002629.SZ) releases a profit forecast, expecting a net profit of 10.5-15.5 million yuan for the year 2024, turning losses into profits compared to the previous year.
Renji Group (002629.SZ) releases the performance forecast for the year 2024, it is expected that the full-year net profit attributable to the shareholders of the listed company...
Zhejiang Renzhi (002629.SZ) has released its performance forecast for the year 2024, with an estimated net profit attributable to shareholders of the listed company of 10.5 million to 15.5 million yuan, turning from a loss to a profit compared to the previous year.
During the reporting period, it is estimated that non-recurring gains and losses will have a cumulative impact of 2 to 3 million yuan on the company's current profit and loss, primarily due to gains and losses from asset sales, provisions for potential liabilities related to investor lawsuits, administrative fines, and bad debt recovery.
Related Articles

On January 5th, BAIRONG-W (06608) spent HK$2.9966 million to repurchase 255,000 shares.

Yifan Pharmaceutical's subsidiary Yifan Pharmaceutical signs an exclusive agreement on an innovative drug.

XUANZHUBIO-B(02575): Xu Yanjun appointed as General Manager.
On January 5th, BAIRONG-W (06608) spent HK$2.9966 million to repurchase 255,000 shares.

Yifan Pharmaceutical's subsidiary Yifan Pharmaceutical signs an exclusive agreement on an innovative drug.

XUANZHUBIO-B(02575): Xu Yanjun appointed as General Manager.

RECOMMEND

Hong Kong Listed Companies’ Return To A Shares Heats Up As New “H To Shenzhen A” Case Emerges
05/01/2026

What Do The Top Ten Biopharma IPOs Of 2025 Tell Us?
05/01/2026

Asia’s Stock Markets Deliver A Strong 2025: Korea Soars 76%, Japan Tops Bubble‑Era Peak, Indonesia Records Best Year In 11 Years
05/01/2026


